Blockchain Registration Transaction Record

Cybin Advances Mental Health Treatments with Q1 2025 Updates and Program Milestones

Cybin Inc. reports Q1 2025 results and key updates on its mental health treatment programs, including Phase 3 expansion for MDD and Phase 2 progress for anxiety disorder.

This news is significant as it highlights Cybin's progress in developing innovative treatments for mental health conditions, such as major depressive disorder and generalized anxiety disorder, which affect millions worldwide. The expansion of the Phase 3 PARADIGM program and the nearing completion of the Phase 2 study for CYB004 represent critical steps toward providing new, effective treatment options for patients who have not benefited from existing therapies. Cybin's work could revolutionize mental healthcare by offering long-lasting relief through intermittent treatments, addressing a significant unmet need in the field.